GLP1R and diabetes mellitus: All the effects of SGLT2i and GLP1-RA on EAT could represent an additional avenue for the treatment of cardiovascular impairments directly or indirectly involved with epicardial fat dysfunction, whether in the presence or absence of diabetes.